CERENOME, INC.

B usiness References to Plus Therapeutics, the Company, we, us and our refer to Plus Therapeutics, Inc. References to Notes refer to the Notes to Financial Statements included herein (refer to Item 8). General Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system ( CNS ) cancers. CNSide Diagnostics, LLC ( CNSide Diagnostics ) is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide , designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium ( 186 Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma ( GBM ), leptomeningeal metastases ( LM ), and pediatric brain cancers ( PBC ) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery ( CED ) and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere ( 188 RNL-BAM ) is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection.